Evidence map›Paper›PMID 26307654›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015

Genome-wide association study of prostate cancer-specific survival.

Robert Szulkin, Robert Karlsson, Thomas Whitington, Markus Aly, Henrik Gronberg, Rosalind A Eeles, Douglas F Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch and 75 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Mendelian Randomization: Concepts and Scope.Cold Spring Harbor perspectives in medicine · 2022
    Review
  5. Review
  6. Review
  7. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. ANO7 is associated with aggressive prostate cancer.International journal of cancer · 2018
    Article
  15. Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Review
  16. Article
  17. Article
  18. Familial prostate cancer.Seminars in oncology · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

85 authors.

Robert SzulkinDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. Academic Primary Healthcare Center, Stockholm County Council, Karolinska Institute, Stockholm, Sweden. robert.szulkin@ki.se.
Robert KarlssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Thomas WhitingtonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Markus AlyDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Henrik GronbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Rosalind A EelesThe Institute of Cancer Research, London, United Kingdom. Royal Marsden National Health Service (NHS) Foundation Trust, London and Sutton, United Kingdom.
Douglas F EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Zsofia Kote-JaraiThe Institute of Cancer Research, London, United Kingdom.
Ali Amin Al OlamaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Sara BenllochCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Kenneth MuirInstitute of Population Health, University of Manchester, Manchester, United Kingdom. Warwick Medical School, University of Warwick, Coventry, United Kingdom.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Melissa C SoutheyGenetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Grattan Street, Parkville, Victoria, Australia.
Liesel M FitzGeraldCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
Brian E HendersonDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
Fredrick R SchumacherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
Csilla SipekyDepartment of Medical Biochemistry and Genetics, Institute of Biomedicine Kiinamyllynkatu 10, University of Turku, Turku, Finland.
Teuvo L J TammelaDepartment of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland.
Børge G NordestgaardDepartment of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Timothy J KeyCancer Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Ruth C TravisCancer Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
David E NealDepartment of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom. Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom.
Jenny L DonovanSchool of Social and Community Medicine, University of Bristol, Bristol, United Kingdom.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom; Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Paul D P PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Nora PashayanCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom. University College London, Department of Applied Health Research, 1-19 Torrington Place, London, United Kingdom.
Kay-Tee KhawClinical Gerontology Unit, University of Cambridge, Cambridge, United Kingdom.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.
Stephen N ThibodeauMayo Clinic, Rochester, Minnesota.
Shannon K McDonnellMayo Clinic, Rochester, Minnesota.
Daniel J SchaidMayo Clinic, Rochester, Minnesota.
Christiane MaierDepartment of Urology, University Hospital Ulm, Ulm, Germany.
Walther VogelInstitute of Human Genetics, University Hospital Ulm, Ulm, Germany.
Manuel LuedekeDepartment of Urology, University Hospital Ulm, Ulm, Germany.
Kathleen HerkommerDepartment of Urology, Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munich, Germany.
Adam S KibelDivision of Urologic Surgery, Brigham and Womens Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Jan LubińskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Wojciech KluźniakInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Lisa Cannon-AlbrightDivision of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Volker HerrmannDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Bernd HolleczekSaarland Cancer Registry, Saarbrücken, Germany.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Thomas A SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Hui-Yi LimBiostatistics Program, Moffitt Cancer Center, Tampa, Florida.
Chavdar SlavovDepartment of Urology and Alexandrovska University Hospital, Medical University, Sofia, Bulgaria.
Radka P KanevaDepartment of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, Bulgaria.
Vanio I MitevDepartment of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, Bulgaria.
Amanda SpurdleMolecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal. Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
Paula PauloDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Sofia MaiaDepartment of Genetics, Portuguese Oncology Institute, Porto, Portugal.
Hardev PandhaThe University of Surrey, Guildford, Surrey, United Kingdom.
Agnieszka MichaelThe University of Surrey, Guildford, Surrey, United Kingdom.
Andrzej KierzekThe University of Surrey, Guildford, Surrey, United Kingdom.
PRACTICAL consortium
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Australia.
Judith A ClementsAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Australia.
Australian Prostate Cancer BioResource
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Gerald L AndrioleWashington University School of Medicine, St. Louis, Missouri.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Stephen ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. Core Genotyping Facility, Frederick National Laboratory for Cancer Research, Gaithersburg, Maryland.
Susan M GapsturEpidemiology Research Program, American Cancer Society, Atlanta, Georgia.
Edward L GiovannucciDepartments of Epidemiology and Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
David J HunterProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Peter KraftProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Loic Le MarchandCancer Research Center of Hawaii, University of Hawaii, Honolulu, Hawaii.
Jing MaDepartment of Medicine, Harvard Medical School, Boston, Massachusetts. Department of Epidemiology, Brigham and Women's Hospital Channing Laboratory, Boston, Massachusetts. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Alison M MondulDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Kathryn L PenneyDepartment of Medicine, Harvard Medical School, Boston, Massachusetts. Department of Epidemiology, Brigham and Women's Hospital Channing Laboratory, Boston, Massachusetts. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Meir J StampferDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Victoria L StevensEpidemiology Research Program, American Cancer Society, Atlanta, Georgia.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece. Department of Hygiene, Epidemiology, and Medical Statistics, University of Athens Medical School, Athens, Greece. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece.
Bas H Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands. Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, United Kingdom. Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Anne TjønnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
David G CoxDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom. Cancer Research Center of Lyon, INSERM UMR1052, Center Léon Bérard, Lyon, France.
BPC3 consortium
Lovise MaehleInherited Cancer Research Group, Department for Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Johanna SchleutkerDepartment of Medical Biochemistry and Genetics, Institute of Biomedicine Kiinamyllynkatu 10, University of Turku, Turku, Finland. BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
Sara LindströmProgram in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

Funding

Southern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0M
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) StudyZIACP010195 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ALBANES, DEMETRIUS · 2009 to 2025
$22.5M
Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3U01CA098758 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2003 to 2010
$11.0M
Epidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6M
Epidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
A genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8M
MULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5M
PLCO Trial Etiologic and Early Marker StudyZ01CP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI HAYES, RICHARD S · 2000 to 2008
$3.3M
NSAIDS and Other Medications in Prostate Cancer EtiologyR01CA092579 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 2001 to 2005
$3.2M
Cancer Research UK 10119Cancer Research UK 10124Cancer Research UK 13065Cancer Research UK 14136Cancer Research UK 15007Cancer Research UK 16491Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK 19170Intramural NIH HHS Z01 CP010152Intramural NIH HHS ZIA CP010195Medical Research Council G0401527Medical Research Council G1000143NCI NIH HHS N01 CN045035NCI NIH HHS N01 CN045165NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA056678NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA072818NCI NIH HHS R01 CA082664NCI NIH HHS R01 CA092447NCI NIH HHS R01 CA092579NCI NIH HHS R01 CA128813NCI NIH HHS R01 CA128978NCI NIH HHS U01 CA098758NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537
6 · The paper itself

Abstract

backgroundUnnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical.

methodsWe performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR).

resultsWe observed no significant association between genetic variants and prostate cancer survival.

conclusionsCommon genetic variants with large impact on prostate cancer survival were not observed in this study. IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes.

Indexed as

Genome-Wide Association StudyHumansMalePolymorphism, Single NucleotideProstatic NeoplasmsSurvival Analysis

Identifiers

PMID26307654
PMCPMC5674990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.